Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing
Executive Summary
Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.
You may also be interested in...
Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
No Break For Sanofi: Seals Another Diabetes Deal
Having just secured a deal with Hanmi Pharmaceutical for its long-acting diabetes products, Sanofi has wasted no time in boosting its diabetes franchise again, by entering into an agreement with Lexicon Pharmaceuticals for sotagliflozin.